Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
(Hinzugefügt: 13.04.2021 um 09:47 Uhr)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
(Hinzugefügt: 12.04.2021 um 18:16 Uhr)